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Abstract  
Background: Hepatitis B, C and HIV infections and their impact forms one of the major health 
problems worldwide and in Sudan. Studies of hepatitis B, C and HIV virus among hemophiliacs in 
Sudan are lacking.   
Objectives: The main objective is to determine the screening, vaccination, seroconversion of 
hepatitis B, C and HIV among Sudanese hemophilic patients registered in Hemophilia Center 
Khartoum Teaching Hospital. 
Methods: During the period from July to November 2008, sixty two hemophilic male patients were 
randomly selected from hemophilic patients attending Hemophilic Center and were studied using 
simple direct standardized interview questionnaire and a blood sample from each patient was taken 
after consent for screening for hepatitis B, C and HIV. 
Results: Out of the 62 patients, 39 (62.9%) were found to be screened before this study.   Out of 
these 23(58.97%) were fully vaccinated for HB V, 23.08 % were partially vaccinated and seven had 
no vaccination at all.  
Only one patient had seroconverted to HBsAg positive. HCV was detected in eight patient one of 
them was also found to have HIV infection.  
Conclusion: The low figures of HBs Ag positivity we got in this study is probably an under 
estimation of the actual prevalence of HBV as we did not use other serological marker and modern 
technology for detection of exposure to HBV. To determine the real magnitude of the problem we 
have to applying other markers like HBc Antibody in the screening procedures which are simple 
and cost effective. The coverage of our hemophilic patients with HBV vaccine was 52% so a 
significant number of our patients are at risk of contracting HBV. Unlike HIV, HCV was detected 
in an alarming percentage. Health education is a cornerstone in prevention of these serious viral 
infections.  
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emophilia is an X linked  hereditary 
bleeding disease  characterized   by 
deficiency of factor VIII (HA) or 
factor IX (HB) which is also known as 
Christmas disease.  The clinical 
manifestations of hemophilia correlate with 
the level of factor VIII and IX. 
Bleeding - spontaneous  or secondary to 
trauma or surgery- may occur at any site of 
the body but the most common sites are the 
joints(80%)  whereas bleeding in  the CNS is  
the most serious site1.
Female carriers of hemophilia have variable 
factor levels so they may be prone to bleeding 
during surgery or after trauma2.
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Treatment is with concentrated factor VIII or 
IX depending on the type of hemophilia 
although some patients may need transfusion 
with whole blood when they develop massive 
hemorrhage. These treatments will subject the 
patients to blood borne infections including 
HBV, HCV and HIV. The majority of the 
studies looking into this issue worldwide were 
old (in the1980s), and were lacking in Sudan. 
Although viral inactivation and the use of 
recombinant technologies and the 
administration of HBV vaccine has 
significantly eliminated viral transmission via 
blood product transfusion, still HBV, HCV 
and HIV infections remain important causes 
of morbidity and mortality in countries where 
these technologies are unavailable.  
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Methodology: This is a prospective 
descriptive, hospital based study done at 
Khartoum Teaching Hospital (K.T.H) –
Hemophilia Centre. 
Sixty two patients were randomly selected 
from patients registered in the Hemophilia 
Centre during the period from Jul-Oct 2008.   
Selection criteria: all male patients known to 
be hemophilic (aged 5 to 40 years) and seen 
regularly in the Hemophilia Centre in K.T.H 
Exclusion criteria: female patients, patients 
with bleeding tendency other than hemophilia 
e.g., platelets disorders vWD, patients who 
underwent surgical operations in the last 6 
months and patients who underwent invasive 
investigations e.g. endoscopy, cystoscopy, 
colonoscopy etc.. were excluded. 
The patients were informed about the study 
and consents were taken. Each patient was 
interviewed using simple direct standardized 
interview questionnaire to obtain information 
about the personal data, past medical history 
including the previous transfusions, the state 
of vaccination for HBV. Clinical examination 
was carried out and blood sample for 
screening for HBsAg, HCV and HIV was 
taken from each patient. Patients with positive 
results were further investigated for the liver 
function test, and were referred to specialized 
centers for further management when needed. 
Results were analyzed, discussed and 
recommendations suggested. 
Results: A total number of 62 hemophilic 
male patients was the sample size, 52 of them 
had HA. The  mean  age was  22.5 years  the  
youngest  patient was  five  years  old  were 
as  the  eldest  was  40 years  old (figure  1). 
Figure (1): shows the distribution of patients 
depending on age. 
Fifty two (83 .9 %)  of  the patients  have  
hemophilia A (HA)  and  so  they  receive 
factor 8  (F VIII)  concentrate  as  treatment   
 
while  16.1 percent  had hemophilia B (HB)  
and  receive  factor  9 (F IX ) concentrate. 
The majority of the patients (72.6 %) have 
positive family history of hemophilia and 
82.3 % of the studied groups were resident in 
Khartoum state. 
If  we  exclude  the  students  then 47.5%  
were  working  while  52.5  % were jobless  
(Table  1), and the majority (88.7%) were 
unmarried. 
 
Table(1): shows the distribution of 
Hemophilic patients depending on 
occupation. 
 
Out of these 62 patients 39 were tested before 
for HBV, HCV and HIV and the result was 
negative for all these viruses. Although  none  
was  positive  for  HBsAg,  only 23 (58.97%)  
received three doses of vaccine against HBV , 
while 3 (7.69%) received two doses , 6 
(15.38%) received a single dose, and the 
remaining 7 (17.95%) received no vaccine    
at all .  
Screening for HBsAg, HCV and HIV   was 
performed on 38 (98.4%) of our studied 
patients after many years of anti-hemophilia 
treatment. 
In this study we screened all the 62 
hemophilic patients (including the 39 patients 
who were screened before) and we detect 
only one (1.61%) patients to be positive for 
HBs Ag, eight (13%) patients as positive for 
HCV and one patient from the eight was also 
positive for HIV. 
Although 13 (21%) patients have past history 
of jaundice, but none shows stigmata of 
chronic liver disease. 
 
Percent Frequency Occupation 
59.7 37Student 
6.5 4Employment 
12.9 8Free work 
21.0 13No work 
100.0 62Total 
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Discussion: The  issue of transmitting  HBV, 
HCV and  HIV to hemophilic patients  has  
been  reduced remarkably by screening  
donated  blood  and  viricidal   techniques  
and  through development  of  recombinant  
products  although  patients  treated  with  old  
concentrate  factor VIII and IX  were  at  risk  
of contracting  infections  with  HIV, HBV, 
HCV3, 4. In one study  the prevalence  of 
antibody  to HCV  was found  to  be 83% in  
patients  infused  for  the  first  time  before  
1985  compared  to 6% in  80  patients  
infused  for  the  first  time  between  1985-
19915. The risk  of  donating  blood  in  the  
window period and  hence  of  post  
transfusion transmission  of  HBV was  
estimated  to  be  1/63000 in  the  united  
states  of  America6.
To the best of our knowledge studies 
concerning the prevalence of HBV, HCV and 
HIV among hemophilic patients was not done 
before in Sudan.  In this study data of 62 
hemophilic male patients were collected. 
Their ages ranged between 5 and 40   years.   
Five years of age was chosen   to   exclude 
patients who contracted the virus vertically 
from infected mothers. 
Seventy percent of our patients’ ages ranged 
between 10 and 30 years and this reflect the 
improvement in early diagnosis and proper 
management of hemophilia. 
Before the extensive usage of replacement 
therapy, patients with severe hemophilia had 
shortened life span and poor quality of life. 
Life expectancy had increased from 11 years 
before 1960s in severe hemophilic to more 
than 50 – 60 years in the 19807.
A round 59.7% of our studied patients were 
students, 19.3% were working. If we exclude 
the group of students then the percentage of 
nonworking patients will be 52%.  Being 
vulnerable to trauma may explain that. This 
has a negative economic and social impact on 
patients and their families (table 1.)  
The majority (82.26%) of our    patients 
reside in Khartoum state.  This  percent does  
not  reflect the  actual  distribution  of  
patients  throughout  the  states  of  the  Sudan  
because  patients from  far  states  were  
coming  less  frequently  to  the  center for  
follow up.     
Only a minority (11.3%) of our patients were 
married. This issue was not thoroughly 
discussed in literature but could  be  explained  
by  the fact that  in  addition  to  the 
psychosomatic  impact  of  the  disease,  the  
majority  of  these patients were  also without  
work.  In fact acceptance  to  marry   a 
hemophilic  patient may be  associated  with  
great  hesitance  from  the females. 
More than 72% of  our patients have  positive  
family  history  of  hemophilia  , these  figures   
are    similar  to  the  world  distribution  of  
hemophilia7.
Screening for HBsAg   was performed on 
62.9% of our patients.  The screening 
program for HBV which was started in 20028
and that for HCV and HIV in 2006 had 
stopped temporary for different reasons.      
The  vast  majority  of  patients  were  
screened  for  HBs Ag, HCV and HIV  after  
many  years  of  receiving  anti  hemophilic  
factors.    
Despite being negative for HBs Ag,   only 
37.1% of the study population had received 
the three   doses, 4.84%       had   two    doses, 
9.68%      only   one dose   and the   
remaining (48.39%) received   no vaccine at 
all.  This may reflect negligence and 
carelessness and occasionally ignorance about 
the importance of vaccination and the 
seriousness of the infections.  Past   history   
of   jaundice was seen in 20.97% of our 
patients. Although excessive hemolysis   
secondary to repeated     transfusions, viral 
hepatitis like HCV (which is detected in eight 
of our patients) may partially explain that, 
however, further investigation to detect other 
causes may be necessary.   
HBV is highly endemic in Sudan.  The 
seroprevalence of HBs Ag was reported to 
range between 5 and 7% in the community 
and 26% in hospital outpatients9, 10. Only one 
patient (1.6%) was positive for HBs Ag. This 
patient had seroconverted during therapy 
period as he was negative for HBsAg in the 
previous screening, but unfortunately he did 
not receive vaccination against HBV.  
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This figure is far less than the 75.6 % reported 
elsewhere and also less than the 51.2% that 
was reported from Japan11. However, those 
high figures reported in the literature were in 
era before implementation of the new 
viricidal inactivation   procedures and before 
vaccination of HBV had become popular, and 
the Japanese study had used PCR and other 
HBV markers which are more sensitive tests 
for detection of current or previous infection. 
Also another  factor  is  that  the  studied  
Japanese  hemophilic  patients  were  older  
than our  patients  and  so  their  risk  of  
contracting  HBV  infection  through other  
routs  like  sexual  transmission  is  higher  
than  our  patients.   
Before the era of modern screening and 
sterilization technology,  unsterilized blood 
products such cryoprecipitate were the major 
cause of very high prevalence of HCV 
positivity among hemophilic  patients  
reaching up to  90% in some countries12, 13 .  
This was probably behind the fact that HCV 
was the major pathogen leading to chronic 
liver disease in these patients with 
hemophilia14. In Sudan HCV was detected in 
0.4% of blood donors, 4.5% in patients with 
Schistosomiasis and in 5.5% in multiply 
transfused patients. Eight (13%) patients in 
this study were positive for HCV15, 16. There 
is no clear explanation for this relatively high 
figure. 
Although it was estimated by the WHO to be 
1.1%, the prevalence of HIV infection in 
Sudan is currently unknown especially after 
the separation of Southern Sudan. Only one 
(0.016%) patient in this hemophilic 
population was positive for HIV, but 
unfortunately this patient was also positive for 
HCV. This is again far less than the high rate 
(55 %) of HIV reported from Japan. After 
using the modern inactivation procedures no 
documented HIV transmission in hemophilics 
was reported from there17. The negative 
impact of HIV and progression of liver 
pathology to cirrhosis and hepatic failure is 
well known in such co-infection18,19.
Conclusions: 
 The low figures of HBs Ag 
positivity we got in this study is probably an 
under estimation of the actual prevalence of 
HBV as we did not use other serological 
marker and modern technology for detection 
of exposure to HBV. To determine the real 
magnitude of the problem we have to 
applying other markers like HBc Antibody in 
the screening procedures which are simple 
and cost effective. The coverage of our 
hemophilic patients with HBV vaccine was 
52% so a significant number of our patients 
are at risk of contracting HBV. Unlike HIV, 
HCV was detected in an alarming percentage. 
Health education is a cornerstone in 
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